3 results
We propose a phase II study (intervention) in patients with severe generalized recessive dystrophic EB receiving reduced toxicity conditioning chemotherapy followe by cord blood transplantation with co-infusion of mesenchymal stromal cell units.…
Safety and performance will be based on a comparison of overall success rates of the Barricaid ARDand either a concurrent group (nonrandomized) of control patients treated by conventional surgicalmethods (e.g., noninstrumented discectomy) at select…
To find the optimal dose of neladenoson bialanate for the Phase III trial by detecting and characterizing a significant dose-response relationship in the two primary efficacy endpoints, absolute change from baseline in LVEF and log-transformed NT-…